Live Breaking News & Updates on Alliance For Clinical Trials In Oncology

Stay updated with breaking news from Alliance for clinical trials in oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Study Reveals Worse Clinical Outcomes in Breast Ca

Study Reveals Worse Clinical Outcomes in Breast Ca
newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.

Chicago , Illinois , United-states , New-york , American , Wendy-chen , Shipra-gandhi , Roswell-park , National-cancer , National-cancer-institute , Roswell-park-comprehensive-cancer-center , Department-of-medicine

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population

Adverse events were consistent with known side effect. ....

China , United-states , Chinese , Harout-semerjian , Drug-administration , Alliance-for-clinical-trials-in-oncology , Nasdaq , Exchange-commission , Glycomimetics-inc , Chinese-national-medical-products-administration , Chief-executive-officer , Clinical-trials

Uproleselan Plus Chemotherapy Misses Phase 3 Trial OS End Point in R/R AML

Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.

....

China , United-states , Chinese , Harout-semerjian , Chinese-national-medical-products-administration , National-cancer-institute , Alliance-for-clinical-trials-in-oncology , Clinical-trials , Hematologic-oncology , News , Acute-myeloid-leukemia , Uprolesan

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […] ....

Michael-morrissey , Peter-lamb , Jennifer-chan , Cabo-atezo , Monty-pal , Laura-dillard , Neeraj-agarwal , Joe-catanzaro , Dana-aftab , Broad-institute , Alliance-for-clinical-trials-in-oncology

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer. ....

Margaret-gatti-mays , Erin-frances-cobain , Monika-burness , Breast-cancer-clinical-research-team , Alliance-for-clinical-trials-in-oncology , University-of-michigan-rogel-cancer-center , Onclive-institutional-perspectives , Michigan-rogel-cancer-center , Ann-arbor , Clinical-trials , D , Early-stage-breast-cancer